Cargando…
Double-Blind, Placebo-Controlled, Randomized Study Comparing 0.0003% Calcitriol with 0.1% Tacrolimus Ointments for the Treatment of Endemic Pityriasis Alba
Background. Pityriasis alba (PA) is a frequent cause of consultation in tropical areas due to its chronic course, frequent relapses, and notorious hypopigmented lesions in pediatric dark skin populations. Currently, no treatment is widely accepted. Objective. To assess the efficacy of 0.0003% calcit...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3346967/ https://www.ncbi.nlm.nih.gov/pubmed/22577371 http://dx.doi.org/10.1155/2012/303275 |
_version_ | 1782232252568043520 |
---|---|
author | Moreno-Cruz, Berenice Torres-Álvarez, Bertha Hernández-Blanco, Diana Castanedo-Cazares, Juan Pablo |
author_facet | Moreno-Cruz, Berenice Torres-Álvarez, Bertha Hernández-Blanco, Diana Castanedo-Cazares, Juan Pablo |
author_sort | Moreno-Cruz, Berenice |
collection | PubMed |
description | Background. Pityriasis alba (PA) is a frequent cause of consultation in tropical areas due to its chronic course, frequent relapses, and notorious hypopigmented lesions in pediatric dark skin populations. Currently, no treatment is widely accepted. Objective. To assess the efficacy of 0.0003% calcitriol and 0.1% tacrolimus ointments compared with placebo in the treatment of endemic PA. Methods. Twenty-eight children aged 3–17 years with 56 symmetrical lesions and phototype IV-V, were randomly assigned to receive the treatments on target lesions on the face. Improvement was evaluated at baseline and 8 weeks later clinically and by digital quantification of the affected area, colorimetry, and transepidermal water loss (TEWL). Results. Tacrolimus and calcitriol ointments induced a mean improvement of 68%, compared to 44% of placebo. We found an elevated TEWL in PA lesions. In the treated plaques, the reduction of the affected area was associated with improvement of pigmentation and TEWL. Conclusions. Calcitriol and tacrolimus induced similar repigmentation in endemic PA lesions. Melanogenic, anti-inflammatory, and barrier defect restoration properties of these drugs may explain these findings. |
format | Online Article Text |
id | pubmed-3346967 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-33469672012-05-10 Double-Blind, Placebo-Controlled, Randomized Study Comparing 0.0003% Calcitriol with 0.1% Tacrolimus Ointments for the Treatment of Endemic Pityriasis Alba Moreno-Cruz, Berenice Torres-Álvarez, Bertha Hernández-Blanco, Diana Castanedo-Cazares, Juan Pablo Dermatol Res Pract Clinical Study Background. Pityriasis alba (PA) is a frequent cause of consultation in tropical areas due to its chronic course, frequent relapses, and notorious hypopigmented lesions in pediatric dark skin populations. Currently, no treatment is widely accepted. Objective. To assess the efficacy of 0.0003% calcitriol and 0.1% tacrolimus ointments compared with placebo in the treatment of endemic PA. Methods. Twenty-eight children aged 3–17 years with 56 symmetrical lesions and phototype IV-V, were randomly assigned to receive the treatments on target lesions on the face. Improvement was evaluated at baseline and 8 weeks later clinically and by digital quantification of the affected area, colorimetry, and transepidermal water loss (TEWL). Results. Tacrolimus and calcitriol ointments induced a mean improvement of 68%, compared to 44% of placebo. We found an elevated TEWL in PA lesions. In the treated plaques, the reduction of the affected area was associated with improvement of pigmentation and TEWL. Conclusions. Calcitriol and tacrolimus induced similar repigmentation in endemic PA lesions. Melanogenic, anti-inflammatory, and barrier defect restoration properties of these drugs may explain these findings. Hindawi Publishing Corporation 2012 2012-04-22 /pmc/articles/PMC3346967/ /pubmed/22577371 http://dx.doi.org/10.1155/2012/303275 Text en Copyright © 2012 Berenice Moreno-Cruz et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Clinical Study Moreno-Cruz, Berenice Torres-Álvarez, Bertha Hernández-Blanco, Diana Castanedo-Cazares, Juan Pablo Double-Blind, Placebo-Controlled, Randomized Study Comparing 0.0003% Calcitriol with 0.1% Tacrolimus Ointments for the Treatment of Endemic Pityriasis Alba |
title | Double-Blind, Placebo-Controlled, Randomized Study Comparing 0.0003% Calcitriol with 0.1% Tacrolimus Ointments for the Treatment of Endemic Pityriasis Alba |
title_full | Double-Blind, Placebo-Controlled, Randomized Study Comparing 0.0003% Calcitriol with 0.1% Tacrolimus Ointments for the Treatment of Endemic Pityriasis Alba |
title_fullStr | Double-Blind, Placebo-Controlled, Randomized Study Comparing 0.0003% Calcitriol with 0.1% Tacrolimus Ointments for the Treatment of Endemic Pityriasis Alba |
title_full_unstemmed | Double-Blind, Placebo-Controlled, Randomized Study Comparing 0.0003% Calcitriol with 0.1% Tacrolimus Ointments for the Treatment of Endemic Pityriasis Alba |
title_short | Double-Blind, Placebo-Controlled, Randomized Study Comparing 0.0003% Calcitriol with 0.1% Tacrolimus Ointments for the Treatment of Endemic Pityriasis Alba |
title_sort | double-blind, placebo-controlled, randomized study comparing 0.0003% calcitriol with 0.1% tacrolimus ointments for the treatment of endemic pityriasis alba |
topic | Clinical Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3346967/ https://www.ncbi.nlm.nih.gov/pubmed/22577371 http://dx.doi.org/10.1155/2012/303275 |
work_keys_str_mv | AT morenocruzberenice doubleblindplacebocontrolledrandomizedstudycomparing00003calcitriolwith01tacrolimusointmentsforthetreatmentofendemicpityriasisalba AT torresalvarezbertha doubleblindplacebocontrolledrandomizedstudycomparing00003calcitriolwith01tacrolimusointmentsforthetreatmentofendemicpityriasisalba AT hernandezblancodiana doubleblindplacebocontrolledrandomizedstudycomparing00003calcitriolwith01tacrolimusointmentsforthetreatmentofendemicpityriasisalba AT castanedocazaresjuanpablo doubleblindplacebocontrolledrandomizedstudycomparing00003calcitriolwith01tacrolimusointmentsforthetreatmentofendemicpityriasisalba |